Fabrication and in vivo thrombogenicity testing of nitric oxide generating artificial lungs

Journal of Biomedical Materials Research - Part A

Volumn 101, Issue 12, 2013, Pages 3511-3519

  Amoako, Kagya A ^a   Montoya, Patrick J ^b   Major, Terry C ^a   Suhaib, Ahmed B ^a   Handa, Hitesh ^a   Brant, David O ^a   Meyerhoff, Mark E ^a,c   Bartlett, Robert H ^a   Cook, Keith E ^a,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MedArray Inc   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

artificial lung; biocompatibility; extracorporeal circulation; nitric oxide; silicone; thrombosis

Indexed keywords

ACTIVATED CLOTTING TIME; ARTIFICIAL LUNG; CONTROL CIRCUITS; COPPER PARTICLES; EXTRACORPOREAL CIRCULATION; FIBRINOGEN CONCENTRATION; THROMBOGENICITY; THROMBOSIS;

BIOCOMPATIBILITY; COPPER; FIBERS; NITRIC OXIDE; OXYGENATORS; SILICONES;

ARTIFICIAL ORGANS;

COPPER; FIBRINOGEN; NITRIC OXIDE; SILICONE;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL LUNG; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD FLOW; CATALYST; CONTROLLED STUDY; COPPER BLOOD LEVEL; EXTRACORPOREAL CIRCULATION; FIBRINOGEN BLOOD LEVEL; HEART OUTPUT; HOLLOW FIBER; HOLLOW FIBER MEMBRANE; HYPOTENSION; MALE; MATERIALS TESTING; MEAN ARTERIAL PRESSURE; NONHUMAN; RABBIT; THROMBOCYTE COUNT; THROMBOGENICITY;

ARTIFICIAL LUNG; BIOCOMPATIBILITY; EXTRACORPOREAL CIRCULATION; NITRIC OXIDE; SILICONE; THROMBOSIS;

ANIMALS; ARTIFICIAL ORGANS; BLOOD CELL COUNT; BLOOD PLATELETS; COPPER; FIBRINOGEN; HEMODYNAMICS; LUNG; NITRIC OXIDE; RABBITS; REGIONAL BLOOD FLOW; S-NITROSOTHIOLS; THROMBOSIS; TIME FACTORS; TISSUE ENGINEERING;

EID: 84886726068     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34655     Document Type: Article

References (31)

1. Conrad SA, Zwischenberger JB, Grier LR, Alpard SK, Bidani A,. Total extracorporeal arteriovenous carbon dioxide removal in acute respiratory failure: A phase I clinical study. Intensive Care Med 2001; 27: 1340-1351.
2. Vaslef SN,. Implantable artificial lungs: Fantasy or feasibility. Landes Biosci 2001; 116-126.
3. Zwischenberger JB, Conrad SA, Alpard SK, Grier LR, Bidani A,. Percutaneous extracorporeal arteriovenous CO2 removal for severe respiratory failure. Ann Thorac Surg 1999; 68: 181-187.
4. Wang D, Lick SD, Zhou X, Liu X, Benkowski RJ, Zwischenberger JB,. Ambulatory oxygenator right ventricular assist device for total right heart and respiratory support. Ann Thorac Surg 2007; 84: 1699-1703.
5. Larson DF, Arzouman D, Kleinert L, Patula V, Williams S,. Comparison of Sarns 3M heparin bonded to Duraflo II and control circuits in a porcine model: Macro- and microanalysis of thrombi accumulation in circuit arterial filters. Perfusion 2000; 15: 13-20.
6. Larm O, Larsson R, Olsson P,. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 1983; 11: 161-173.
7. Tayama E, Hayashida N, Akasu K, Kosuga T, Fukunaga S, Akashi H, Kawara T, Aoyagi S,. Biocompatibility of heparin-coated extracorporeal bypass circuits: New heparin bonded bioline system. Artif Organs 2000; 24: 618-623.
8. Engbers GH, Feijen J,. Current techniques to improve the blood compatibility of biomaterial surfaces. Int J Artif Organs 1991; 14: 199-205.
9. Palanzo DA, Zarro DL, Manley NJ, Montesano RM, Quinn M, Elmore BA, Gustafson PA, Castagna JM,. Effect of Carmeda-BioActive surface coating versus TrilliumTM biopassive surface coating bypass coating of the oxygenator on circulating platelet count drop during cardiopulmonary bypass. Perfusion 2001; 16: 279-283.
10. Kim WS, Jacobs H,. Design of nonthrombogenic polymer surfaces for blood-contacting medical devices. Blood Purif 1996; 14: 357-372.
11. Do YS, Kao EY, Ganaha F, Minamiguchi H, Sugimoto K, Lee J, Elkins CJ, Amabile PG, Kuo, Wang DS, Waugh JM, Dake,. In-stent restenosis limitation with stent-based controlled-release nitric oxide: Initial results in rabbits. Radiology 2004; 230: 377-382.
12. Palmer RM, Ferrige AG, Moncada S,. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 337: 524-526.
13. Kolpakov V, Gordon D, Kulik TJ, Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995; 76: 305-309.
14. Major TC, Brant DO, Reynolds MM, Bartlett RH, Meyerhoff ME, Handa H, Annich GM,. The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer. Biomaterials 2010; 31: 2736-2745.
15. Major TC, Brant DO, Burney CP, Amoako KA, Annich GM, Meyerhoff ME, Handa H, Bartlett RH,. The hemocompatibility of a nitric oxide generating polymer that catalyzes S-nitrosothiol decomposition in an extracorporeal circulation model. Biomaterials 2011; 32: 5957-5969.
16. Colman RW, Hirsh J, Marder VJ, Clowes AW, George NJ,. Hemostasis and Thrombosis: Basic Principles & Clinical Practice, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins,; 2001.
17. Wu Y, Rojas AP, Grifth GW, Skrzypchak AM, Lafayette N, Bartlett RH, Meyerhoff ME,. Improving blood compatibility of intravascular oxygen sensors via catalytic decomposition of S-nitrosothiols to generate nitric oxide in situ. Sens Actuators B Chemi 2007; 121: 36-46.
18. Oh BK, Meyerhoff ME,. Catalytic generation of nitric oxide from nitrite at the interface of polymeric films doped with lipophilic Cu(II)-complex: A potential route to the preparation of thromboresistant coatings. Biomaterials 2004; 25: 283-293.
19. Amoako KA, Cook KE,. Nitric oxide-generating silicone as a blood-contacting biomaterial. ASAIO J 2012; 58: 539-544.
20. Amoako KA, Archangeli C, Major TC, Meyerhoff ME, Annich GM, Bartlett RH,. Thromboresistance characterization of extruded nitric oxide releasing silicone catheters. ASAIO J 2012; 58: 238-246.
21. Amoako KA,. Nitric oxide therapies for local inhibition of platelets' activation on blood-contacting surfaces. PhD Dissertation, University of Michigan; 2012.
22. Maugeri N, Rovere-Querini R, Evangelista V, Covino C, Capobianco A, Bertilaccio MTS, Piccoli A, Totani L, Cianflone D, Maseri A, Manfredi AA,. Neutrophils phagocytose activated platelets in vivo: A phosphatidylserine, P-selectin, and integrin-dependent cell clearance program. Blood 2009; 113: 5254-5265.
23. Fufa D, Shealy B, Jacobson M, Kevy S, Murray M,. Activation of platelet-rich plasma using soluble type I collagen. J Oral Maxillofac Surg 2008; 66: 684-690.
24. Tevaearai HT, Mueller XM, Tepic S, Cotting J, Boone Y, Montavon PM, and, Von Segesser LK,. Nitric oxide added to the sweep gas infusion reduces local clotting formation in adult blood oxygenators. ASAIO J 2000; 46: 719-722.
25. Kwaan HC, Walter Bowie EJ,. Thrombosis. Philadelphia, PA: W.B. Saunders Company; 1982.
26. Grunkemeier JM, Tsai WB, McFarland CD, Horbett TA,. The effect of adsorbed fibrinogen, fibronectin, von Willebrand factor and vitronectin on the procoagulant state of adherent platelets. Biomaterials 2000; 21: 2243-2252.
27. Wu Y, Zhou Z, Meyerhoff ME,. In vitro platelet adhesion on polymeric surfaces with varying fluxes of continuous nitric oxide release. J Biomed Mater Res Part A 2007; 81: 956-963.
28. Gawaz M, Langer H, May AE,. Platelets in inflammation and atherogenesis. JClin Invest 2005; 115: 3378-3384.
29. Weber C,. Platelets and chemokines in atherosclerosis: Partners in crime. Circ Res 2005; 96: 612-616.
30. Furie B, Furie BC,. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: Role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost 1995; 74: 224-227.
31. Cha W, Meyerhoff ME,. Catalytic generation of nitric oxide from S-nitrosothiols using immobilized organoselenium species. Biomaterials 2007; 28: 19-27.